Mitigating alemtuzumab-associated autoimmunity in MS: a “whack-a-mole” B-cell depletion strategy Meltzer E, Campbell S, Ehrenfeld B, et al. Neurol Neuroimmunol Neuroinflamm 2020; 7:e868. Abstract Objective To determine whether the punctuated administration of low-dose rituximab, temporally linked to B-cell hyperrepopulation (defined when the return of CD19+ B cells approximates 40%-50% of baseline levels as measured before alemtuzumab […]
Which drug reduces the autoimmune risks of alemtuzumab? — Neurochecklists Blog
from The Neurology Lounge https://ift.tt/350othw
Comments
Post a Comment